Skip to main content
OpenTrials
Completed

NCT Number: NCT06957210

Post-Traumatic Growth Following Eye Movement Desensitization and Reprocessing Therapy Versus SSRIs in Patients With Post-Traumatic Stress Disorder

This randomized controlled trial investigates the comparative effectiveness of Eye Movement Desensitization and Reprocessing (EMDR) therapy and selective serotonin reuptake inhibitors (SSRIs) in fostering post-traumatic growth among patients diagnosed with post-traumatic stress disorder (PTSD). Participants will be randomized to receive either EMDR therapy or standard SSRI pharmacotherapy. The primary objective is to evaluate the extent of psychological growth and recovery achieved through each intervention, aiming to guide future therapeutic strategies for PTSD.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

PTSD - Post Traumatic Stress Disorder Combat Disorders Mental Disorders Stress Disorders, Post-Traumatic Stress Disorders, Traumatic Trauma and Stressor Related Disorders

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Combined Military Hospital, Nowshera, KPK, Pakistan

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Clinical diagnosis of Post-Traumatic Stress Disorder (PTSD) based on DSM-5 criteria

Willingness to participate and provide informed consent

Ability to comply with study procedures

Exclusion criteria

Current diagnosis of psychotic disorder, bipolar disorder, or severe major depressive episode with psychotic features

Active substance use disorder within the past 6 months

Severe cognitive impairment or inability to complete study assessments

Treatment and study plan

EMDR

Behavioral

Participants will receive structured EMDR therapy sessions conducted by trained therapists following standard EMDR protocols. Sessions will occur weekly over a 6 week period.

SSRIs

Drug

Participants will receive pharmacotherapy with an SSRI prescribed according to standard clinical guidelines for PTSD, monitored by a psychiatrist over a 6-week period.

Primary outcomes

  1. Post-Traumatic Growth (PTG) measured by Post-Traumatic Growth Inventory (PTGI)

    Time frame: 6 weeks

    Change in PTGI total score from baseline to 6 weeks.

Secondary outcomes

  1. PTSD symptom severity measured by PTSD Checklist

    Time frame: 6 weeks

    Change in PTSD Checklist total score from baseline to 6 weeks.

Sponsors and collaborators

Lead sponsor

Asad Ullah Jan

Other Gov

Registry information

Official study title

Post-Traumatic Growth Following Eye Movement Desensitization and Reprocessing Therapy Versus SSRIs in Patients With Post-Traumatic Stress Disorder: A Randomized Controlled Trial

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
May 4, 2025
Registry last updated
May 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.